• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Biotech

    Pliant, Acelyrin take ‘poison pills’ as Concentra buyout looms

    FIERCE BIOTECH

    ACELRYIN: Concentra Biosciences` Interest Unlikely to Top Alumis

    GLOBENEWSWIRE

    Alumis and ACELYRIN Confirm Merger Benefits

    GLOBENEWSWIRE

    ACELRYN and Alumis Confirm Merger`s Strategic Rationale

    GLOBENEWSWIRE

    Acelyrin Announces Phase 2 And Phase 3 Data For Lonigutamab

    GLOBENEWSWIRE

    Acelyrin to Host Event to Share Ph 2 & Ph 3 Data for Lonigutamab

    GLOBENEWSWIRE

    Acelyrin Terminates Izokibep After Failed Phase IIb/III Uveitis Data

    BIOSPACE

    Acelyrin Reports Izokibep Phase 2b/3 Results For Uveitis

    GLOBENEWSWIRE

    Acelyrin Forms Advisory Board Featuring Voices In Thyroid Eye Disease

    GLOBENEWSWIRE

    Acelyrin Announces Positive Lonigutamab Phase 1/2 Data

    GLOBENEWSWIRE

    ACELYRIN: Izokibep Phase 2b/3 PsA Data At EULAR 2024 Late-Breaker

    GLOBENEWSWIRE

    ACELYRIN Lonigutamab Phase 1/2 Data At ENDO 2024 Late-Breaker

    GLOBENEWSWIRE

    ACELYRIN, INC. Announces Positive Ph 1/2 Proof-of-Concept Data for Lonigutamab

    GLOBENEWSWIRE

    ACELYRIN Announces Positive Results from Phase 2b/3 Trial of Izokibep

    GLOBENEWSWIRE

    Could a CRO error explain Acelyrin`s shocking phase 3 failure?

    FIERCE BIOTECH

    Acelyrin says CRO Fortrea made errors in trial of lead immunology drug izokibep

    ENDPTS

    ACELYRIN Announces Results from Placebo-Controlled Clinical Trial of Izokibep

    GLOBENEWSWIRE

    Acelyrin Announces Magnitude of Clinical Responses with Izokibep

    PR NEWSWIRE

    Acelyrin Announces Izokibep Achieves HiSCR100 Responses at 12 Weeks

    PR NEWSWIRE

    ACELYRIN, INC. to Accelerate Development of Izokibep in Hidradenitis Suppurativa

    PR NEWSWIRE

    ACELYRIN Furthers Leadership Position Immunology with Acquisition of ValenzaBio

    BIOSPACE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.